Spectrum Pharmaceuticals Announces Presentation Of SPI 1620 Data At The AACR NCI EORTC International Conference

Spectrum Pharmaceuticals, Inc., (Nasdaq: SPPI) announced that preclinical data on SPI-1620 was presented via poster presentations at the International Conference of the AACR-NCI-EORTC on Molecular Targets and Cancer Therapeutics, being held in San Francisco October 22-26, 2007. SPI-1620 is a drug that is being developed for use with chemotherapy. [click link for full article]

More: continued here

Filed under: Cancer on October 25th, 2007